Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.50 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | PPM1B | O75688 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CPN1 | P15169 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6050362 | 0.90 | SLC6A1 (0.47) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL6063290 | 0.90 | PPM1B (0.41) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL13610195 | 0.88 | TSHR (0.45) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL24489216 | 0.88 | TSHR (0.45) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL31221629 | 0.88 | TSHR (0.45) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL134525 | 0.86 | SLC6A1 (0.53) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL132089 | 0.86 | SLC6A1 (0.53) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL132090 | 0.86 | SLC6A1 (0.53) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL205293 | 0.85 | SLC6A1 (0.52) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL22444028 | 0.85 | SLC6A1 (0.52) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778712-B1 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | Univ Virginia Patent Found (US) | 2013-01-30 | — | — | EP | claimed |
| CN-101209990-B | Resolution method for 3-piperidine formic acid ester | Jiangsu tianzhi chemical co ltd | 2010-11-10 | — | — | CN | claimed |
| US-7605143-B2 | 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-10-20 | — | — | US | claimed |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | claimed |
| US-7396825-B2 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-07-08 | — | — | US | claimed |
| CN-101209990-A | Resolution method for 3-piperidine formic acid ester | JIANGSU TIANZHI CHEMICAL CO LT (CN) | 2008-07-02 | — | — | CN | claimed |
| JP-2008508360-A | — | — | 2008-03-21 | — | — | JP | claimed |
| EP-1496911-B1 | USE OF A COMBINATION COMPRISING A2A ADENOSINE RECEPTOR AGONISTS AND ANTI-PATHOGENIC AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIV VIRGINIA (US) | 2007-12-19 | — | — | EP | claimed |
| EP-1778712-A2 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-05-02 | — | — | EP | claimed |
| EP-1746885-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATMENT OF DIABETIC NEPHROPATHY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-01-31 | — | — | EP | claimed |
| US-20060040888-A1 | 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-02-23 | — | — | US | claimed |
| WO-2006015357-A2 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2006-02-09 | — | — | WO | claimed |
| US-20050261236-A1 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-24 | — | — | US | claimed |
| WO-2005107463-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATMENT OF DIABETIC NEPHROPATHY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-11-17 | — | — | WO | claimed |
| US-20050182018-A1 | Method to reduce inflammatory response in transplanted tissue | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-18 | — | — | US | claimed |
| EP-1496911-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-01-19 | — | — | EP | claimed |
| EP-1434782-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | University of Virginia Patent Foundation (US) | 2004-07-07 | — | — | EP | claimed |
| WO-2003086408-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-10-23 | — | — | WO | claimed |
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-02 | — | — | US | claimed |
| WO-2003029264-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-04-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261236-A1 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | ADORA2A, ADORA3, PDE4A | SLC6A1 2771/4885SLC6A11 2584/4885TSHR 412/4885 |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | ADORA2A, PDE4A, PDE4B | SLC6A1 2717/4885SLC6A11 3048/4885TSHR 1139/4885 |
| US-20050182018-A1 | Method to reduce inflammatory response in transplanted tissue | ADORA2A, PDE4A, PDE4B | SLC6A1 2841/4885SLC6A11 3044/4885TSHR 1392/4885 |
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | ADORA2A, ADORA1, ADORA3 | SLC6A1 1997/4885SLC6A11 2803/4885TSHR 256/4885 |
| US-20060040888-A1 | 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity | ADORA2A, ADORA3, ADORA1 | SLC6A1 3039/4885SLC6A11 3419/4885TSHR 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.